Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy

Therapeutic Apheresis and Dialysis

Volumn 14, Issue 5, 2010, Pages 451-456

  Hasegawa, Midori ^a   Kondo, Fumiko ^b   Yamamoto, Koichiro ^a   Murakami, Kazutaka ^a   Tomita, Makoto ^a   Nabeshima, Kunihiro ^a   Nakai, Shigeru ^c   Kato, Masao ^b   Ohashi, Atsushi ^c   Arai, Jiro ^d   Hiki, Yoshiyuki ^c   Ishii, Junichi ^a   Emi, Nobuhiko ^a   Sugiyama, Satoshi ^e   Yuzawa, Yukio ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY HOSPITAL   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

^d Medical & Biological Laboratories Co Ltd   (Japan)

^e Kanayama Clinic   (Japan)

Author keywords

Acute renal failure; Bortezomib; Dexamethasone; Free light chain; Hemodiafiltration; Myeloma cast nephropathy

Indexed keywords

BORTEZOMIB; CREATININE; DEXAMETHASONE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTIFICIAL KIDNEY; BONE MARROW EXAMINATION; CLINICAL ARTICLE; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DRUG MEGADOSE; FEMALE; HEMODIAFILTRATION; HEMODIALYSIS; HUMAN; KIDNEY BIOPSY; KIDNEY DISEASE; LABORATORY DIAGNOSIS; LIGHT CHAIN; MALE; MULTIPLE MYELOMA; PLASMA VOLUME; PLASMAPHERESIS; PRIORITY JOURNAL;

ACUTE KIDNEY INJURY; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HEMODIAFILTRATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA EXCHANGE; PYRAZINES; TREATMENT OUTCOME;

EID: 77957333484     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2010.00863.x     Document Type: Conference Paper

References (15)

1. Blade J, Fernandez-Llama P, Bosch F et al. Renal failure in multiple myeloma: a presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998 158 : 1889 1893.
2. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000 65 : 175 181.
3. Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003 78 : 21 33.
4. Korbet SM, Schwartz MM. Multiple Myeloma. J Am Soc Nephrol 2006 17 : 2533 2545.
5. Augustson BM, Begum G, Dunn JA et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom medical research council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005 23 : 9219 9226.
6. Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008 22 : 1485 1493.
7. El-Achkar TM, Sharfuddin AA, Dominguez J. Approach to acute renal failure with multiple myeloma: role of plasmapheresis. Ther Apher Dial 2005 9 : 417 422.
8. Clark WF, Stewart AK, Rock GA et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005 143 : 777 784.
9. Hutchison CA, Bradwell AR, Cook M et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009 4 : 745 754.
10. Hutchison CA, Cockwell P, Reid S et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007 18 : 886 895.
11. Matsuo S, Imai E, Horio M et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009 982 992.
12. Leung N, Gertz MA, Zeldenrust SR et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008 73 : 1282 1288.
13. Cserti C, Haspel R, Stowell C, Dzik W. Light-chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion 2007 47 : 511 514.
14. Chanan-Khan AA, Kaufman JL, Mehta J et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007 109 : 2604 2606.
15. Ludwig H, Drach J, Graf H, Lang A, Meran JG. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007 92 : 1411 1414.